Navigation Links
Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus

olerated. Frequency and severity of adverse events were similar to placebo, with no increase at higher doses. Among the Phase 2 study findings was a significantly improved response rate among serologically active patients at Week 52, as defined by an improvement in SELENA SLEDAI score of 4 points or greater, no new BILAG A flare and no more than one new BILAG B flare, and no worsening in Physician's Global Assessment (46% for LymphoStat-B versus 29% for placebo, p<0.01). This combination of measures is the primary efficacy endpoint in the Phase 3 clinical trials.

The data presented at EULAR 2007 demonstrated that LymphoStat-B continued to reduce the signs and symptoms of SLE disease activity throughout the 24- week extension phase of the study, demonstrated durable clinical and biological activity at Week 76, and appeared safe and well tolerated, with no increase in frequency and or severity of adverse events. The evidence of continuing improvement from Week 52 to Week 76 includes:

    -- An increase from 46% to 56% among serologically active patients in the

       patient response rate selected as the primary efficacy endpoint of the

       Phase 3 trials.


    -- An increase from 29% to 38% in the reduction in SLE disease activity

       among serologically active patients, as measured by SELENA SLEDAI.


    -- An increase from 33% to 41% in the reduction in SLE disease activity

       among serologically active patients, as measured by the Physician's

       Global Assessment.


    -- An increase in the mean improvement in health-related quality of life

       from 3.0 points to 3.4 points among serologically active patients, as

       measured by the SF-36 Physical Component Summary score.


    -- A durable reduction in anti-dsDNA autoantibodies (at least 50% or

       negative) among patients who were positive for anti-dsDNA at baseline

       (30% at Week 52; 34% at Week 76).


    -- Durable or increased reductions from Week 52 t
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Testing for Human Papillomavirus
2. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
3. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
4. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
5. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
6. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
7. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
8. NCI Researchers Discover Genes That Are Turned on at High Levels in Tumor-associated Blood Vessels of Mice and Humans
9. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
10. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
11. Human Genome Sciences Announces Positive Final Results Of Phase 2b Trial of Albuferon
Post Your Comments:
(Date:8/29/2014)... SPRING, Md. , Aug. 29, 2014  United ... that the U.S. District Court for the District of ... its favor in the company,s case against Sandoz, Inc. ... Judge Peter Sheridan ruled that U.S. Patent ... Inc., and enjoined Sandoz from marketing its generic product ...
(Date:8/29/2014)... August 29, 2014 According ... Product & Services (Equipment, Reagent, Primer, Probe, Custom ... PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) - ... global Oligonucleotide Synthesis Market is expected to reach ... 2014, growing at a CAGR of 9.8% from ...
(Date:8/29/2014)... , Aug. 29, 2014  Unilife Corporation ("Unilife" or ... today that it intends to release its financial results ... June 30, 2014 after market trading ends on Tuesday, ... a conference call for 4:30 p.m. U.S. EDT on ... 6:30 a.m. AEST), to review the Company,s financial results, commercial ...
Breaking Medicine Technology:District Court Decision Received In Remodulin Patent Case 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2
... Sinovac Biotech Ltd. (Nasdaq: SVA ), a leading ... release its unaudited financial results for the first quarter ended ...  The Company will host a conference call on Tuesday, May ... 8:00 p.m. China Standard Time) to review the Company,s financial ...
... Perrigo Company (Nasdaq: PRGO ; TASE) today ... 2012. (Logo:   http://photos.prnewswire.com/prnh/20120301/DE62255LOGO ) ... "We are very pleased with our record fiscal third ... made possible by the continued operational excellence of the ...
Cached Medicine Technology:Sinovac to Host Conference Call to Report First Quarter 2012 Unaudited Financial Results 2Perrigo Reports Record Third Quarter Revenue And Earnings And Raises Full Year EPS Guidance 2Perrigo Reports Record Third Quarter Revenue And Earnings And Raises Full Year EPS Guidance 3Perrigo Reports Record Third Quarter Revenue And Earnings And Raises Full Year EPS Guidance 4Perrigo Reports Record Third Quarter Revenue And Earnings And Raises Full Year EPS Guidance 5Perrigo Reports Record Third Quarter Revenue And Earnings And Raises Full Year EPS Guidance 6Perrigo Reports Record Third Quarter Revenue And Earnings And Raises Full Year EPS Guidance 7Perrigo Reports Record Third Quarter Revenue And Earnings And Raises Full Year EPS Guidance 8Perrigo Reports Record Third Quarter Revenue And Earnings And Raises Full Year EPS Guidance 9Perrigo Reports Record Third Quarter Revenue And Earnings And Raises Full Year EPS Guidance 10Perrigo Reports Record Third Quarter Revenue And Earnings And Raises Full Year EPS Guidance 11Perrigo Reports Record Third Quarter Revenue And Earnings And Raises Full Year EPS Guidance 12Perrigo Reports Record Third Quarter Revenue And Earnings And Raises Full Year EPS Guidance 13Perrigo Reports Record Third Quarter Revenue And Earnings And Raises Full Year EPS Guidance 14Perrigo Reports Record Third Quarter Revenue And Earnings And Raises Full Year EPS Guidance 15Perrigo Reports Record Third Quarter Revenue And Earnings And Raises Full Year EPS Guidance 16Perrigo Reports Record Third Quarter Revenue And Earnings And Raises Full Year EPS Guidance 17Perrigo Reports Record Third Quarter Revenue And Earnings And Raises Full Year EPS Guidance 18
(Date:8/30/2014)... 2014 Ms. Meriwether’s striking beauty is not ... has an impressive resume to boost. Nana is best ... However, she’s also a two time All American UCLA ... trained for the 2008 Olympics and played professional volleyball as ... six-foot beauty from Potomac, Maryland is a two-time, All American ...
(Date:8/30/2014)... Tampa, FL (PRWEB) August 30, 2014 ... operated full service auto repair shop with strong ties to ... McLeod Family is happy to announce they have been chosen ... number one pick for auto repair. , Tim McLeod’s ... Park Auto Service sixty years ago. Although his son, Tim ...
(Date:8/30/2014)... As 500 Zoloft lawsuits pending ligation contend the ... mothers, Wright & Schulte LLC recently learned of a remand ... remand in the Zoloft lawsuits was granted to ... involved in one SSRI lawsuit filed jointly under ... defect lawsuit sent back to the Missouri state court in ...
(Date:8/30/2014)... Barton Associates, an industry leading national physician, physician ... announces a new office location in Austin, TX, scheduled ... in Peabody, MA, with additional staffing centers in Hardwick, ... , Barton Associates decided to expand its workforce ... The United States is in the midst of a ...
(Date:8/30/2014)... CT (PRWEB) August 30, 2014 ... national observance that educates Americans about the fact ... by recovery, from alcohol and drug addiction and ... organizations join with treatment providers, prevention programs and ... heals individuals, families, workplaces and neighborhoods. The ...
Breaking Medicine News(10 mins):Health News:NJ Top Dentists Announces Cover Model for the Healthy Living: Top Dentists Issue 2Health News:McLeod's Sunset Park Auto Service Celebrates 60 Years Honored with Best of South Tampa 2Health News:Group of Plaintiffs in Zoloft Lawsuit Alleging SSRI Caused Birth Defect Are Granted Remand 2Health News:Group of Plaintiffs in Zoloft Lawsuit Alleging SSRI Caused Birth Defect Are Granted Remand 3Health News:Group of Plaintiffs in Zoloft Lawsuit Alleging SSRI Caused Birth Defect Are Granted Remand 4Health News:Group of Plaintiffs in Zoloft Lawsuit Alleging SSRI Caused Birth Defect Are Granted Remand 5Health News:Barton Associates Announces New Office Location in Austin, TX 2Health News:September is National Recovery Month: What the Connecticut Community for Addiction Recovery (CCAR) Wants You to Know 2Health News:September is National Recovery Month: What the Connecticut Community for Addiction Recovery (CCAR) Wants You to Know 3
... high-tech, high-power men,s skincare ... exclusively at Barney,s, NEW YORK, April 16 The ... thousands of,products to meet their needs, now gives men some ... renowned men,s skincare line,steps it up with the introduction of ...
... 16 Abbott (NYSE:,ABT) announced today that it ... Labour and Welfare for HUMIRA(R) (adalimumab) for the,treatment ... to,conventional therapy. This approval is the first for ... HUMIRA with Eisai Co., Ltd. HUMIRA,is now approved ...
... Healthcare,Management Group, Inc. (Phyhealth) (Pink Sheets: PHYH), a ... physicians,today announced that it has filed with the ... December 31, 2005, December 31, 2006, and,the nine ... of filing its,historical financials, Phyhealth expects to be ...
... - Worldwide Sales Growth of 13.8 Percent - ... - Worldwide Medical Products Sales Increased 13.7 Percent - ... First Quarter -, ABBOTT PARK, Ill., April 16 Abbott (NYSE:,ABT) today ... * Diluted earnings per share, excluding specified items, were ...
... Ore. Oregon Health & Science University researchers have ... cells. , This finding is important because expression ... such as lymphoma and breast cancers, said Charles Lopez, ... of Medicine., The research will be presented at a ...
... 16 The Blackstone,Group has today informed us that ... in Gerresheimer AG, held by BCP Murano II S.a.r.l. ... by Credit Suisse, 7.8 million,shares will be sold to ... exit its Gerresheimer investment after Gerresheimer,s IPO,in June 2007. ...
Cached Medicine News:Health News:Mens Luxury Skincare Market Grows 2Health News:Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis 2Health News:Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis 3Health News:Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis 4Health News:Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis 5Health News:Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis 6Health News:Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis 7Health News:Phyhealth Files Historical Financials With the Pink Sheets and Takes Next Step Toward Becoming Fully Reporting 2Health News:Abbott Reports Double-Digit Sales and Earnings Growth in First Quarter and Reaffirms Full-Year Growth Outlook 2Health News:Abbott Reports Double-Digit Sales and Earnings Growth in First Quarter and Reaffirms Full-Year Growth Outlook 3Health News:Abbott Reports Double-Digit Sales and Earnings Growth in First Quarter and Reaffirms Full-Year Growth Outlook 4Health News:Abbott Reports Double-Digit Sales and Earnings Growth in First Quarter and Reaffirms Full-Year Growth Outlook 5Health News:Abbott Reports Double-Digit Sales and Earnings Growth in First Quarter and Reaffirms Full-Year Growth Outlook 6Health News:Abbott Reports Double-Digit Sales and Earnings Growth in First Quarter and Reaffirms Full-Year Growth Outlook 7Health News:Abbott Reports Double-Digit Sales and Earnings Growth in First Quarter and Reaffirms Full-Year Growth Outlook 8Health News:Abbott Reports Double-Digit Sales and Earnings Growth in First Quarter and Reaffirms Full-Year Growth Outlook 9Health News:Abbott Reports Double-Digit Sales and Earnings Growth in First Quarter and Reaffirms Full-Year Growth Outlook 10Health News:Abbott Reports Double-Digit Sales and Earnings Growth in First Quarter and Reaffirms Full-Year Growth Outlook 11Health News:Abbott Reports Double-Digit Sales and Earnings Growth in First Quarter and Reaffirms Full-Year Growth Outlook 12Health News:Abbott Reports Double-Digit Sales and Earnings Growth in First Quarter and Reaffirms Full-Year Growth Outlook 13Health News:Abbott Reports Double-Digit Sales and Earnings Growth in First Quarter and Reaffirms Full-Year Growth Outlook 14Health News:Abbott Reports Double-Digit Sales and Earnings Growth in First Quarter and Reaffirms Full-Year Growth Outlook 15Health News:Abbott Reports Double-Digit Sales and Earnings Growth in First Quarter and Reaffirms Full-Year Growth Outlook 16Health News:Abbott Reports Double-Digit Sales and Earnings Growth in First Quarter and Reaffirms Full-Year Growth Outlook 17Health News:Abbott Reports Double-Digit Sales and Earnings Growth in First Quarter and Reaffirms Full-Year Growth Outlook 18
... a rapid, real-time thermal cycler used for ... automating much of the testing process, and ... is the fastest, easiest to use, and ... The SmartCycler delivers highly accurate and consistent ...
... is a rapid, real-time thermal cycler used ... By automating much of the testing process, ... it is the fastest, easiest to use, ... market. The SmartCycler delivers highly accurate and ...
... The SmartCycler System is a rapid, ... from prepared biological samples. By automating much ... reaction site individually programmable, it is the ... system now on the market. The SmartCycler ...
... is a rapid, real-time thermal cycler used ... By automating much of the testing process, ... it is the fastest, easiest to use, ... market. The SmartCycler delivers highly accurate and ...
Medicine Products: